International Journal of Infertility & Fetal Medicine

Register      Login

VOLUME 6 , ISSUE 2 ( May-August, 2015 ) > List of Articles

RESEARCH ARTICLE

Naloxone Breeding Effectiveness in Rat Suffering from Nitric Oxide-induced Polycystic Ovary Syndrome

Manizheh Karami, Fatemeh Lakzaei, MohammadReza Jalali Nadoushan

Citation Information : Karami M, Lakzaei F, Nadoushan MJ. Naloxone Breeding Effectiveness in Rat Suffering from Nitric Oxide-induced Polycystic Ovary Syndrome. Int J Infertil Fetal Med 2015; 6 (2):67-72.

DOI: 10.5005/jp-journals-10016-1104

Published Online: 00-08-2015

Copyright Statement:  Copyright © 2015; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Background and objective

Polycystic ovary syndrome (PCOS) can be induced in Wistar rats by over production of nitric oxide (NO). This study evaluated the efficacy of naloxone on the breeding characteristics of rats suffering from nitric oxide induced PCOS.

Materials and methods

Twenty-four female Wistar rats(200–250 gm) were kept as virgin under standard conditions. They were divided into four groups (n = 6). One group of the animals received L-arginine (50 mg/kg) intraperitoneally (i.p.) for 9 days/once a day. Another group was administered naloxone hydrochloride (0.4 mg/kg, i.p.) prior to injection of L-arginine. The third group was injected solely naloxone. Control group received saline solution (1 ml/kg, i.p.). After the treatments, all female rats were coupled with the intact males. They were then separated by observation of vaginal plaques; it was considered as day 0 of pregnancy. Eventually, they were operated on days 18 to 19 of the gestation to collect the animals’ ovaries. The samples were studied for pathological evidence. The fetal number and weight along with the fetal crown-rump length (CRL) were measured.

Results

The ovaries obtained from the L-arginine treated group had large cysts with thickened granulosa cell layer in contrast to those of the control or naloxone treated rats (p < 0.0001). The number of fetus though showed a decrease in the L-arginine treated rats (3 ± 1), but the fetal weight or fetal CRL did not change (p > 0.05).

Conclusion

This study may clearly illustrate the polycystic characteristics in the L-arginine treated group. It may particularly display the breeding efficacy of naloxone in rats with PCOS.

How to cite this article

Karami M, Lakzaei F, Nadoushan MRJ. Naloxone Breeding Effectiveness in Rat Suffering from Nitric Oxide-induced Polycystic Ovary Syndrome. Int J Infertil Fetal Med 2015;6(2):67-72.


PDF Share
  1. Clinical gynecologic endocrinology and infertility. 7th ed. New York: Lippincott Williams and Wilkins; 2005. p. 485-513.
  2. Screening women with polycystic ovarian syndrome for metabolic syndrome. Obstet Gynecol 2005; 106(1): 131-137.
  3. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90(4):1929-1935.
  4. Nitric oxide and fibrinogen in polycystic ovary syndrome: Associations with insulin resistance and obesity. Eur J Obstet Gynecol Reprod Biol 2007 Aug;133(2):191-196.
  5. Cell-specific localization of nitric oxide synthases (NOS) in the rat ovary during follicular development, ovulation and luteal formation. Hum Reprod 1996; 11(12):2667-2673.
  6. The regulation and pharmacology of endothelial nitric oxide synthase. Annu Rev Pharmacol Toxicol 2006;46:235-276.
  7. Changes in nitric oxide synthase activity in the ovary of gonadotropin treated rats: the role of nitric oxide during ovulation. Endocrin J 1999;46(4):529-538.
  8. Nitric oxide-induced polycystic ovaries in the Wistar rat. Int J Fertil Steril 2012;6(2):111-116.
  9. A novel inhibitory effect of naloxone on macrophage activation and atherosclerosis formation in mice. J Am Coll Cardiol 2006; 48(9):1871-1879.
  10. Self-administration of intravenous buprenorphine and the buprenorphine/naloxone combination by recently detoxified heroin abusers. J Pharmacol Exp Ther 2002 Nov;303(2):695-703.
  11. Opioid-glutamate-nitric oxide connection in the regulation of luteinizing hormone secretion in the rat. Endocrinology 1998;139(3):955-960.
  12. Microscopic characterization of follicular structures in letrozole-induced polycystic ovarian syndrome in the rat. Arch Med Res 2006;37(7):830-839.
  13. Physiology of reproduction, in the laboratory rat: the handbook of experimental animal. Hrinke CJ, editor. London: Academic press; 2000. p. 145-176.
  14. Induction of endometriosis by implantation of endometrial fragments in female rats. Iran J Reprod Med 2006;4(2):63-67.
  15. A new rat model exhibiting both ovarian and metabolic characteristics of polycystic ovary syndrome. Endocrinology 2007;148(8):3781-3791.
  16. The involvement of nitric oxide in the ovulatory process in the rat. Endocrinology 1994;135(5): 2287-2290.
  17. Nitric oxide: an autocrine regulator of human granulosa-luteal cell steroidogenesis. Endocrinology 1994;135(5):1799-1806.
  18. Gonadotropin stimulated regulation of blood-follicle barrier is mediated by nitric oxide. Am J Physiol 1995;269(2 Pt 1):E29O-E298.
  19. Inhibition of nitric oxide effects on IL-lb-enhanced ovulation rate, steroid hormones, and ovarian leukocyte distribution at ovulation in the rat. Biol Reprod 1996;54(2):436-445.
  20. Serum retinol-binding protein 4, leptin, and plasma asymmetric dimethylarginine levels in obese and non obese young women with polycystic ovary syndrome. Fertil Steril 2011;96(1):246-250.
  21. Asymmetric dimethylarginine (ADMA) and endothelial dysfunction: implications for atherogenesis. Clinics (Sao Paulo) 2009;64(5): 471-478.
  22. Asymmetrical imethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment. J Clin Endocrinol Metab 2008;93(1):82-90.
  23. Effect of bee venom on IL-6, COX-2 and VEGF levels in polycystic ovarian syndrome induced in Wistar rats by estradiol valerate. J Venom Anim Toxins Incl Trop Dis 2013;19(1):19-32.
  24. Effect of long-term naltrexone treatment on endocrine profile, clinical features, and insulin sensitivity in obese women with polycystic ovary syndrome. Fertil Steril 2002;77(5):936-944.
  25. Role of opioid antagonists in the treatment of women with glucoregulation abnormalities. Curr Pharm Des 2006;12(8):1001-1012.
  26. Involvement of ovarian steroids in the opioid mediated reduction of insulin secretion in hyperinsulinemic patients with polycystic ovary syndrome. J Clin Endocrinol Metab 1998;83(5):1742-1745.
  27. Animal models for study of polycystic ovaries and ovarian atresia. In: Dhindsa DS, Anderson E, Kalra SP, editors. Regulation of ovarian and testicular function. New York: Plenum; 1987. p. 237-258.
  28. Characterization of ovarian follicular cysts and associated endocrine profiles in dairy cows. Biol Reprod 1995;53(4):890-898.
  29. Polycystic ovarian syndrome: temporal characterization of the induction and reversion process in an experimental model. Braz J Vet Res Anim Sci 2004 Nov-Dec;41(6):389-395.
  30. Interferon-g and tumor necrosis factor induce the l-arginine-dependent cytotoxic effector mechanism in murine macrophages. Eur J Immunol 1988;18(10):1587-1592.
  31. Nitric oxide: a physiologic mediator of penile erection. Science 1992 Jul 17;257(5068):401-403.
  32. The role of leukocytes and cytokines as paracrine regulators in the mechanisms of ovulation. In: Fujimoto S, Hsueh AJW, Strauss IH, editors. Frontiers in Endocrinology. New York: Ares-Serono Symposium Pub; 1995;13. p. 225-233.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.